Quarterly Form 13Fs reveal stock movements of top fund managers, including Stanley Druckenmiller’s exits from Nvidia and Palantir. Duquesne’s chief invests in a drugmaker consistently. AI remains a hot trend on Wall Street, but profit-taking and skepticism prompt Druckenmiller’s shift to drug stocks. Nvidia and Palantir soar, but sustainability and valuation concerns linger. Druckenmiller’s focus on Teva Pharmaceutical Industries hints at a different investment strategy. Teva’s legal wins and innovative drug development make it a compelling pick. Druckenmiller’s increasing stake in Teva signals confidence in its growth potential and attractive valuation. Consider Stock Advisor’s top 10 stock picks for potentially higher returns, excluding Teva. Sean Williams has positions in Teva, Nvidia, and Palantir.

Read more at Nasdaq: Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street’s Hottest Drug Stocks Ahead of 2026